Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor, a cardiovascular risk marker: results from a randomized, double-blind, placebo-controlled, multicenter North American clinical trial.

When evaluating the reduction in systolic BP within the group consuming nattokinase, the decrease from 144±1.5 mmHg to 140±2.1 mmHg reached a statistical trend ( P <0.1).

also in 1,557 other papers

Plasma renin activity The average PRA did not change in either group and did not reach statistical significance when comparing the nattokinase and the placebo groups.

also in 75,278 other papers

The reduction in diastolic BP was highly significant for males consuming nattokinase, where the average baseline diastolic BP at 86 mmHg dropped to 81±2.5 mmHg after 8 weeks of consuming nattokinase, in contrast to the placebo group where the diastolic BP remained constant at 88±2.6 mmHg ( P <0.006).

also in 82,236 other papers